Clinical Pharmacology of Miami, Llc

Miami, Florida 33172-3161

4 studies enrolling now · 59 studies all time

What they study most

Autoimmune and Chronic Inflammatory Diseases, Cardiometabolic Disease, Chronic Hepatitis D Infection, Contrast Enhancement in Magnetic Resonance Imaging, Cystic Fibrosis, Diabetic Neuropathic Pain, Elevated CRP, Endometriosis Related Pain, Health Volunteers, Healthy, Healthy Participants, Healthy Subjects

Studies at this site

• Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity — Recruiting now
• First in Human Study in Subjects With Obesity, But Otherwise Healthy — Recruiting now
• Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment — Recruiting now
• A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants — Recruiting now
• A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations — Completed
• A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP — Running, not enrolling
• A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. — Completed
• A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function — Completed
• Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function — Completed
• Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity — Completed
• A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment — Completed
• Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity — Completed
• A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function — Completed
• A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants — Stopped early
• A Phase 1a Study of PMN310 In Healthy Volunteers — Completed
• A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally — Completed
• Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment — Completed
• HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes — Completed
• A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function — Completed
• Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days — Completed
• Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels — Stopped early
• Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH — Completed
• A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function — Completed
• A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function — Completed
• Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity — Stopped early
• Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment — Completed
• Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite — Completed
• Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment — Completed
• Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old — Completed
• Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function — Completed
• The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis — Completed
• A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant — Completed
• A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment — Completed
• A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants — Completed
• A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants — Completed
• Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment — Completed
• Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function — Completed
• A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics — Completed
• A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function — Completed
• Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis — Status unconfirmed
• Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects — Completed
• Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers — Completed
• Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects — Completed
• A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants — Completed
• Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment — Completed
• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers — Completed
• Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants — Completed
• Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration — Completed
• Study of Single-dose DS-3201b in Participants With Hepatic Impairment — Completed